Ubiquitination and E3 Ubiquitin Ligases in Rare Neurological Diseases with Comorbid Epilepsy

Jiuhe Zhu1, Nien-Pei Tsai2

  • 1Department of Molecular and Integrative Physiology, School of Molecular and Cellular Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.

Neuroscience
|January 14, 2020
PubMed

Insights

Ubiquitination, a key protein regulator, is increasingly linked to epilepsy. This review explores how its dysregulation contributes to neurological disorders and epilepsy, focusing on rare conditions.

Area of Science:

  • Molecular Biology
  • Neuroscience
  • Biochemistry

Background:

  • Ubiquitination regulates protein function, degradation, and transport.
  • Dysfunctional ubiquitination is implicated in severe diseases, including neurological disorders.
  • The specific role of ubiquitination in epilepsy remains under-explored.

Purpose of the Study:

  • To review the role of ubiquitination in neuronal function.
  • To examine recent findings on ubiquitination dysregulation in epilepsy.
  • To highlight ubiquitination's connection to rare neurological disorders with epilepsy.

Main Methods:

  • Literature review of ubiquitination and epilepsy research.
  • Categorization of epilepsy-associated E3 ubiquitin ligases and substrates.
  • Discussion of ubiquitination-related rare neurological disorders.

Main Results:

  • Ubiquitination is vital for neuronal cellular activities, including ion channel trafficking and synaptic receptor turnover.
  • Dysregulation of the ubiquitination/ubiquitin proteasome system (UPS) is increasingly recognized in epilepsy.
  • Specific E3 ubiquitin ligases and their substrates are being identified in epilepsy pathogenesis.

Conclusions:

  • Ubiquitination plays a critical role in neuronal homeostasis and is implicated in epilepsy.
  • Further research into ubiquitination pathways is crucial for understanding and treating epilepsy, especially in rare genetic disorders.
  • Investigating E3 ubiquitin ligases and their substrates offers promising therapeutic targets for epilepsy.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
750
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
555
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
820
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K